Ono/BMS Highlight Low Rates Of Serious Infection With Orencia
This article was originally published in PharmAsia News
Executive Summary
Ono and Bristol Myers Squibb said July 4 that the rate of serious infection, a current problem associated with the administration of biological formulations, is low for biological rheumatoid arthritis drug Orencia (abatacept).